Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
13:43 8/1/2007 TLBT 1-15 R/S ** Tech Laboratories, Inc. Common Stock RNWF Renewal Fuels, Inc. Common Stock
8/1/2007 HMSC 1-100 R/S ** Homeland Security Capital Corporation Common Stock HOMS Homeland Security Capital Corporation NEW Common Stock
.05/.053 PRSU
if it breaks thru HDSN there's no real stop light until FANC at .10...lol....eviltweety may have a good time with that :)
PRSU .048/.05 1x1
hey mary! :)
PRSU L2 (FANC bidding)
.045/.048
PRSU L2 >>.edit ut .048 ask x1
PRSU .048/.05 round somethingorother..LOL congrats!
CTTY naz heads up...coming off bottom .59...up 50%
it's in the press release
congrats MGLG, negger!! .34x2 .355x1
yep, only way to play a shell until it takes the next leap..lol
MGLG up 13% .32/.34 2x2 ...GL :)
actually nolichucky river is 10 min away....rainbow trout :)
i love to fish for crappie, catfish and bass...oh and perch
happy fishing!! :)
SREA L2>>edit ut .205/.22 1x1
PASL L2....u decide
LOL! congrats :)
another shell gone mad?
morning stuff!
MBAH up 37% .0011
u got it!
woog....he sued me for being a shareholder so i guess that one won't work anymore....it's kinda official now.
FSMH my sell just filled in izone...weeeeeeeeeeeeee....only one acct to go..lol
yes, u have posted that several times....i would have to be asleep to have missed it....how about you wait until after market and you'll most likely have a better chance for discussion.
believe me, i wish i had played the momo! awesome call....banging head on desk..lol
andrius....i see nothing about the shares being worthless in the 8K just filed...hard to know what's going to happen...maybe they changed their strategy after the def14 was filed....i dunno...could go either way i guess.
7/31/2007 WWSI 1-3 R/S ** Worldwide Strategies Incorporated Common Stock WWSG Worldwide Strategies Incorporated NEW Common Stock
wahoooooo AESK....congrats lotto players!! awesome call , SL :)
LIV 1.16 Samaritan Exclusively Licenses Innovative Blood Diagnostic to Uncover Whether Breast Tumor is Cancer
Jul 30, 2007 10:22:00 AM
2007 PrimeNewswire, Inc.
Blood Test Can Detect One Single Aggressive Cancer Cell Out of
Millions of Normal Blood Cells
Diagnostic Technology Thought to Detect Prostrate and Colon
Cancer, as Well
LAS VEGAS, July 30, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals, Inc. (AMEX:LIV), a developer of innovative drugs, announced today that it has entered into an exclusive licensing agreement with Georgetown University for an innovative blood test diagnostic that detects whether a breast tumor is cancer and if diagnosed as cancer, the blood test detects the cancer's aggressiveness to metastasize and spread throughout the body.
The innovative cancer diagnostic blood test was discovered as a result of its research and development collaboration with Georgetown University giving Samaritan first rights to license. The diagnostic screens for targeted tumor cell markers and has demonstrated the ability to identify just one circulating breast cancer cell out of millions of normal blood cells.
See peer reviewed journal publications: http://www.samaritanpharma.com/publications_and_patents.asp
Samaritan Pharmaceuticals: "Transforming Today's Science Into Tomorrow's Cures..."
Samaritan Pharmaceuticals is a life science company focused on commercializing innovative drugs to relieve the suffering of patients with Alzheimer's, cancer, heart disease, and infectious disease. Samaritan's business strategy is to partner its later stage drugs after Phase II (proof of concept) human studies and has executed its first partnership for its PII, HIV drug SP-01A, with Pharmaplaz, Ireland. The FDA has authorized an investigational new drug (IND) # and a Phase I for its Alzheimer's drug Caprospinol and Samaritan has several other drugs it is advancing to enter (IND) status. In addition, Samaritan's sales arm has acquired the marketing and sales rights to sell ten revenue-generating products in Greece and various Eastern European countries.
Website, http://www.samaritanpharma.com. Please register so we can notify you of upcoming conference calls, news and events.
The Samaritan Pharmaceuticals Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=2670
Disclaimer
The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings, and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science, and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 13, 2007. The company undertakes no duty to update forward-looking statements.
CONTACT: Samaritan Pharmaceuticals, Inc.
Richard Brown
(702) 735-7001
RichardBrown@SamaritanPharma.com
SPPI 4.05 GPC Biotech Withdraws Satraplatin NDA For Accelerated Approval; Plans to Resubmit With Survival Analysis
Jul 30, 2007 9:48:00 AM
IRVINE, Calif., July 30 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc., (Nasdaq: SPPI) today announced that GPC Biotech has withdrawn the satraplatin New Drug Application (NDA) filed for accelerated approval for the treatment of hormone-refractory prostate cancer. The decision was based on the vote by the Oncologic Drugs Advisory Committee (ODAC) to the U.S. Food and Drug Administration (FDA) on July 24, 2007 that the FDA should wait for the survival analysis of the SPARC trial before deciding whether satraplatin is approvable.
GPC Biotech anticipates overall survival results from the SPARC trial to be available within six months. However, this timing is based on an extrapolation of death rates in the trial and may change.
"We look forward to receiving the overall survival data from the SPARC trial and to the resubmission of the NDA to the FDA next year," stated Luigi Lenaz, M.D., Chief Scientific Officer of Spectrum Pharmaceuticals. "Meanwhile, we plan to aggressively continue the development of Spectrum's diversified pipeline, including, EOquin(R) in Phase 3 clinical trials for non- invasive bladder cancer, and ozarelix in a Phase 2b trial for benign prostate hypertrophy, as we strive to reduce risk and build value for our shareholders by not depending on the success of any single drug or technology."
Spectrum acquired worldwide rights to satraplatin from Johnson Matthey PLC. In 2002, Spectrum licensed worldwide rights to satraplatin to GPC Biotech (Frankfurt Stock Exchange: GPC; TecDAX index; Nasdaq: GPCB). GPC Biotech is responsible for all costs associated with the development and regulatory filings of satraplatin.
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals acquires, develops and commercializes a diversified portfolio of oncology drug candidates that meet critical health challenges for which there are few other treatment options. Spectrum's expertise lies in identifying drugs with demonstrated safety and efficacy, and adding value through further clinical development and selection of the most efficient methods of commercialization. The company's pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients, such as at-home chemotherapy and new treatment regimens for refractory disease. For more information, please visit our website at www.spectrumpharm.com.
Forward-looking statement - This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements include but are not limited to statements that relate to our business and its future, Spectrum's ability to identify, acquire, develop and commercialize its portfolio of drug candidates, the Company's promising pipeline, our team's ability to identify promising drugs and move these drugs through development and toward commercialization, that survival results from the SPARC trial will be available within six months, that the satraplatin NDA will be resubmitted to the FDA next year, that we will aggressively continue the development of our diversified pipeline, that we will reduce risk and build value for our shareholders and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates, may not prove safe or effective, the possibility that our existing and new drug candidates may not receive approval from the FDA, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in- license and develop additional drug candidates may fail, our lack of revenues, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.
COMPANY CONTACTS MEDIA CONTACT
Russell Skibsted Susan Neath
SVP & Chief Business Officer Porter Novelli Life Sciences
619-849-6007
Paul Arndt
Manager, Investor Relations
949-788-6700
SOURCE Spectrum Pharmaceuticals, Inc.
----------------------------------------------
Russell Skibsted
SVP & Chief Business Officer
or Paul Arndt
Manager
Investor Relations
+1-949-788-6700
both of Spectrum Pharmaceuticals; or Susan Neath of Porter Novelli Life Sciences
+1-619-849-6007
GPC Biotech Withdraws Satraplatin NDA For Accelerated Approval; Plans to Resubmit With Survival Analysis
Jul 30, 2007 9:48:00 AM
IRVINE, Calif., July 30 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc., (Nasdaq: SPPI) today announced that GPC Biotech has withdrawn the satraplatin New Drug Application (NDA) filed for accelerated approval for the treatment of hormone-refractory prostate cancer. The decision was based on the vote by the Oncologic Drugs Advisory Committee (ODAC) to the U.S. Food and Drug Administration (FDA) on July 24, 2007 that the FDA should wait for the survival analysis of the SPARC trial before deciding whether satraplatin is approvable.
GPC Biotech anticipates overall survival results from the SPARC trial to be available within six months. However, this timing is based on an extrapolation of death rates in the trial and may change.
"We look forward to receiving the overall survival data from the SPARC trial and to the resubmission of the NDA to the FDA next year," stated Luigi Lenaz, M.D., Chief Scientific Officer of Spectrum Pharmaceuticals. "Meanwhile, we plan to aggressively continue the development of Spectrum's diversified pipeline, including, EOquin(R) in Phase 3 clinical trials for non- invasive bladder cancer, and ozarelix in a Phase 2b trial for benign prostate hypertrophy, as we strive to reduce risk and build value for our shareholders by not depending on the success of any single drug or technology."
Spectrum acquired worldwide rights to satraplatin from Johnson Matthey PLC. In 2002, Spectrum licensed worldwide rights to satraplatin to GPC Biotech (Frankfurt Stock Exchange: GPC; TecDAX index; Nasdaq: GPCB). GPC Biotech is responsible for all costs associated with the development and regulatory filings of satraplatin.
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals acquires, develops and commercializes a diversified portfolio of oncology drug candidates that meet critical health challenges for which there are few other treatment options. Spectrum's expertise lies in identifying drugs with demonstrated safety and efficacy, and adding value through further clinical development and selection of the most efficient methods of commercialization. The company's pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients, such as at-home chemotherapy and new treatment regimens for refractory disease. For more information, please visit our website at www.spectrumpharm.com.
Forward-looking statement - This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements include but are not limited to statements that relate to our business and its future, Spectrum's ability to identify, acquire, develop and commercialize its portfolio of drug candidates, the Company's promising pipeline, our team's ability to identify promising drugs and move these drugs through development and toward commercialization, that survival results from the SPARC trial will be available within six months, that the satraplatin NDA will be resubmitted to the FDA next year, that we will aggressively continue the development of our diversified pipeline, that we will reduce risk and build value for our shareholders and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates, may not prove safe or effective, the possibility that our existing and new drug candidates may not receive approval from the FDA, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in- license and develop additional drug candidates may fail, our lack of revenues, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.
COMPANY CONTACTS MEDIA CONTACT
Russell Skibsted Susan Neath
SVP & Chief Business Officer Porter Novelli Life Sciences
619-849-6007
Paul Arndt
Manager, Investor Relations
949-788-6700
SOURCE Spectrum Pharmaceuticals, Inc.
----------------------------------------------
Russell Skibsted
SVP & Chief Business Officer
or Paul Arndt
Manager
Investor Relations
+1-949-788-6700
both of Spectrum Pharmaceuticals; or Susan Neath of Porter Novelli Life Sciences
+1-619-849-6007
WTVI .001 New Wi-Fi TV Design and Features to Be Previewed in Live Webcast
Jul 30, 2007 9:36:00 AM
NEWPORT BEACH, CA -- (MARKET WIRE) -- 07/30/07 -- Wi-Fi TV Inc. (PINKSHEETS: WTVI) will preview a completely new website design and features in a live webcast on Wednesday, August 8 at 2 PM Pacific time, 5 PM Eastern time and the program will be available thereafter for on-demand viewing at www.Wi-FiTV.com.
"The new third generation of Wi-Fi TV's Social Internet TV has been created to enable Wi-Fi TV to compete globally to become one of the world's most popular consumer websites and to further implement Wi-Fi TV's vision of Internet TV. The design can be viewed on any Internet enabled device from cellular phones to big screen TVs, has been optimized for millions of laptop and desktop PCs, and features a rich array of user interactive video, audio, chat and call technology," said Joe Soto, Wi-Fi TV's Global Vice President.
"The new Wi-Fi TV design will greatly enhance the value of Wi-Fi TV Stations, which are offered to business at $25,000, $50,000 and $100,000 price points, introduce a targeted format for Wi-Fi TV online video ads and banner ads, improve the ease in signing up for Wi-Fi TV for free, and bring an array of new features for viewers," Mr. Soto added.
Wi-Fi TV Chairman Alex Kanakaris will also be demonstrating the new Wi-Fi TV website design in Beijing at iHollywoodChina on August 22 and the BIRTV exposition in China August 22-25.
About Wi-Fi TV
Wi-Fi TV(TM) is a pioneer of TV on the Internet. Wi-Fi TV Inc. has long touted the coming convergence of TV and the Internet, and provided the first online movie in December 1995. The Wi-Fi TV website is the only place on the Internet where you can watch hundreds of TV stations and chat with others watching the same program in a live chat box directly under the viewing screen, and get breaking news for each country and category listed, and download a dialer and make free phone calls and host live video parties all on one website.
Wi-Fi TV Inc. provides Social Internet TV(TM), a new generation TV delivery platform that has a geographic sphere out-distancing any traditional cable or over-the-air TV broadcaster. Wi-Fi TV memberships are free at www.Wi-FiTV.com and include such perks as free online phone calls and free chat and free online parties.
The Company was launched in 1995 and has been publicly traded since November 1997, and has been a pioneer in the delivery of video and books over the Internet.
Press Relations
Wi-Fi TV Inc. has opened a content and technology demo room for the press in Newport Beach, California.
Forward-Looking Statements
Any statements made in this press release which are not historical facts contain certain forward-looking statements; as such term is defined in the Private Security Litigation Reform Act of 1995, concerning potential developments affecting the business, prospects, financial condition and other aspects of the company to which this release pertains. The actual results of the specific items described in this release, and the company's operations generally, may differ materially from what is projected in such forward-looking statements. Although such statements are based upon the best judgments of management of the company as of the date of this release, significant deviations in magnitude, timing and other factors may result from business risks and uncertainties including, without limitation, the company's dependence on third parties, general market and economic conditions, technical factors, the availability of outside capital, receipt of revenues and other factors, many of which are beyond the control of the company. The company disclaims any obligation to update information contained in any forward-looking statement. Wi-Fi TV and Social Internet TV are trademarks of Wi-Fi TV Inc. and all rights pertaining to these names are reserved. This press release shall not be deemed a general solicitation.
For further information contact:
Colby Marceau
(949) 716-9397
info@wi-fitv.com
AVAN .71 AVANT Commences Phase 2 Clinical Trial of Its Single Dose, Oral Typhoid Fever Vaccine
Jul 30, 2007 9:16:00 AM
Copyright Business Wire 2007
NEEDHAM, Mass.--(BUSINESS WIRE)--
AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) announced today the initiation of enrollment in a randomized, placebo-controlled, double-blind Phase 2 study of its typhoid fever vaccine candidate, Ty800, in approximately 180 healthy adult volunteers. The Phase 2 study is an out-patient, dose-ranging clinical trial that will evaluate two dose levels of the single-dose, oral Ty800 vaccine and will follow each subject for six months post-vaccination. The objectives of this Phase 2 study are to determine the optimal dose of Ty800 for further development based on the safety, reactogenicity, and immunogenicity of the vaccine. The study is being conducted by Accelovance Inc. of Rockville, MD at five clinical sites across the United States.
"We are delighted to be initiating clinical testing of our single-dose, oral Ty800 vaccine," said Una S. Ryan, President and Chief Executive Officer of AVANT Immunotherapeutics, Inc. "The development of a safe and effective typhoid fever vaccine is important for protecting residents, travelers and military personnel from typhoid fever in endemic areas. We see the commencement of this trial as serving the dual role of addressing a significant health issue in the developing world and advancing development of AVANT's bacterial vaccine franchise. AVANT is advancing its programs towards creating a "Super Combination Traveler's Vaccine". Our "Super Vaccine" is designed to capture the potential of our single-dose oral delivery platforms to combine protection against multiple bacterial diseases including cholera, typhoid, ETEC (enterotoxigenic E. coli) and paratyphoid into one convenient and efficient vaccine for world travelers."
AVANT has designed the Ty800 vaccine to offer rapid, oral, single-dose protection against Salmonella typhi, the cause of typhoid fever. The Ty800 vaccine was developed using genetic techniques to delete specific genes known to be essential to the virulence of S. typhi. The clinical trial is designed to show that Ty800 is well tolerated in humans and rapidly elicits strong immune responses.
About Typhoid Fever
Typhoid fever is a potentially life-threatening infection of the intestinal tract caused by the bacterium Salmonella typhi. It is transmitted by ingestion of food or water contaminated by the feces from an infected person. According to the Centers for Disease Control, an estimated 22 million cases of typhoid fever and 200,000 related deaths occur worldwide each year. In the United States, incidence of the disease is reported mainly in recent travelers to areas of the world where typhoid fever is endemic. Risk is greatest for travelers to South Asia and developing countries in Asia, Africa, the Caribbean and Central and South America. There are two current vaccines for typhoid fever, a four-dose oral vaccine and an intramuscularly injected vaccine, both of which provide protection to only 50-80% of recipients.
About AVANT Immunotherapeutics, Inc.
AVANT Immunotherapeutics, Inc. discovers and develops innovative vaccines and therapeutics that harness the human immune system to prevent and treat disease. AVANT has three products on the market and four of AVANT's products are in clinical development. AVANT's pipeline includes products for travelers' vaccines and global health needs based on AVANT's oral, rapid-protecting, single-dose and temperature-stable vaccine technology. Additional information on AVANT Immunotherapeutics, Inc. can be obtained through our site on the World Wide Web: http://www.avantimmune.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that are subject to a variety of risks and uncertainties and reflect AVANT's current views with respect to future events and financial performance. There are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking statement made by AVANT. These factors include, but are not limited to: (1) the integration of multiple technologies and programs; (2) the ability to adapt AVANT's vectoring systems to develop new, safe and effective orally administered vaccines against anthrax and plague or other any other microbes used as bioweapons and other disease causing agents; (3) the ability to successfully complete product research and further development, including animal, pre-clinical and clinical studies, and commercialization of CholeraGarde(R) (Peru-15), Ty800, ETEC E. coli vaccine, VLPs and other products and AVANT's expectations regarding market growth; (4) the cost, timing, scope and results of ongoing safety and efficacy trials of CholeraGarde(R) (Peru-15), Ty800, ETEC E. coli vaccine and other preclinical and clinical testing; (5) the ability to negotiate strategic partnerships or other disposition transactions for AVANT's cardiovascular programs, including TP10 and CETi; (6) the ability of AVANT to manage multiple clinical trials for a variety of product candidates; (7) AVANT's expectations regarding its technological capabilities and expanding its focus to broader markets for vaccines; (8) the Company's expectations regarding the cost of funding its development partnership with Select Vaccines Limited for the influenza vaccine, the opportunity to extend to other disease targets, and AVANT's ability to develop products through this collaboration; (9) changes in existing and potential relationships with corporate collaborators; (10) the availability, cost, delivery and quality of clinical and commercial grade materials produced at AVANT's own Manufacturing facility or supplied by contract manufacturers and partners; (11) the timing, cost and uncertainty of obtaining regulatory approvals; (12) the ability to develop and commercialize products before competitors that are superior to the alternatives developed by competitors; (13) the ability to retain certain members of management;(14) AVANT's expectations regarding research and development expenses and general and administrative expenses; (15) AVANT's expectations regarding cash balances, capital requirements, anticipated royalty payments (including those from Paul Royalty Fund), revenues and expenses, including infrastructure expenses; (16) our belief regarding the validity of our patents and potential litigation; and (17) certain other factors that might cause AVANT's actual results to differ materially from those in the forward-looking statements including those set forth under the headings "Business," "Risk Factors" and Management's Discussion and Analysis of Financial Condition and Results of Operations" in each of AVANT's Annual Report on Form 10-K, its Quarterly Reports on Form 8-K, as well as those described in AVANT's other press releases and filings with the Securities and Exchange Commission, from time to time. You should carefully review all of these factors, and you should be aware that there may be other factors that could cause these differences. These forward-looking statements were based on information, plans and estimates at the date of this press release, and AVANT does not promise to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other changes.
Source: AVANT Immunotherapeutics, Inc.
----------------------------------------------
AVANT Immunotherapeutics
Inc.
Una S. Ryan
Ph.D.
781-433-0771
President and CEO
or
Avery W. Catlin
781-433-0771
Chief Financial Officer
info@avantimmune.com
or
For Media:
Kureczka/Martin Associates
Ellen M. Martin
510-832-2044
emm4@pacbell.net
ICOP 7.10 ICOP President and COO Honored by Kansas City Business Journal
Laura Owen Recognized as One of the 'Women Who Mean Business' for 2007
Jul 30, 2007 9:10:00 AM
LENEXA, Kan., July 30 /PRNewswire-FirstCall/ -- ICOP Digital, Inc. (Nasdaq: ICOP), an industry-leading company engaged in advancing digital surveillance solutions, today announced that Laura Owen, the Company's President and Chief Operating Officer, has been recognized by the Kansas City Business Journal for her career accomplishments and significant contributions to business in Kansas City.
Named as one of the publication's "Women Who Mean Business" for 2007, Owen was among 25 women honored this past Friday at the eighth annual awards luncheon, sponsored by the Kansas City Business Journal and its partners - the Ewing Marion Kauffman Foundation, the UMKC Henry W. Bloch School of Business and Public Administration, Mercedes-Benz of Kansas City and M&I Bank. In addition, Owen was featured in a special supplement of the Kansas City Business Journal published on Friday, July 27, 2007.
A successful entrepreneur and business executive, Owen has achieved over 30 years' experience in strategic development and marketing, corporate communications, investment banking, financial consulting, business development, project funding and management, and sales management. Aside from her many current and past accomplishments at ICOP and within the business community at large, Owen has also been active in civic and government affairs in Kansas, including serving as the State's Secretary of Commerce and Housing; Chairperson of the Kansas Department Finance Authority; Chairperson of the Kansas Rural Development Council; Advisory Board Member of the U.S. Committee for Good Common Sense; and Board Member of Heart to Heart International, Children of Promise International and the Annual Guns 'n Hoses Boxing Event; among many other organization and political postings.
With a son on active duty in the U.S. Army and currently deployed in Iraq, Owen has also applied her entrepreneurial skill to help other family members of those serving our country recognize and honor their loved ones who risk their lives everyday to protect and serve - in the military, as well as in the fields of law enforcement and firefighting. With a mission to honor those who serve, Owen created "Heart for a Hero" (www.heartforahero.com) - a national movement centered on a unique, sterling silver, heart-shaped locket bonded with 18k gold that was personally designed and crafted by Owen. In April of this year, a Heart for a Hero locket was formally presented to First Lady Laura Bush.
"Laura is an inexhaustible, amazing woman," stated Dave Owen, Chairman and CEO of ICOP Digital. "Her vision, commitment to excellence and dedication to others has served to define the direction and success of her every endeavor, including that of our Company. We are very proud of her and delighted that she is being honored for her many important accomplishments."
About ICOP Digital, Inc.
ICOP Digital, Inc. protects people, assets and profits, providing a Veil of Protection(TM) for our nation's communities with innovative, mission- critical security, surveillance and communication solutions. The Company engineers, manufactures and markets mobile and stationary surveillance products for use in the public and private sectors, and facilitates the delivery of live video to first responders. The ICOP Model 20/20(R), ICOP's flagship product, is the leading digital in-car video recorder system for law enforcement. The ICOP Guardian(TM) is a stationary IP camera that records high quality video images on a local server, and is capable of activation through several triggers. ICOP LIVE(TM) delivers live streaming video to and from first responder vehicles and headquarters, empowering first responders with enhanced situational awareness, helping to optimize the outcome of a crisis. (GSA Contractor)
For more information, please view the following video presentations at http://www.icopdigital.com/why_icop.html and www.ICOP.com/veil.html, or visit www.ICOP.com.
Safe Harbor Statement
This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties that could cause actual results to vary materially from those projected in the forward-looking statements. The company may experience significant fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, our reliance on third-party manufacturers and suppliers, government agency budgetary and political constraints, new or increased competition, changes in market demand, and the performance or reliability of our products. These factors and others could cause operating results to vary significantly from those in prior periods, and those projected in forward-looking statements. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in certain forms the company has filed with the Securities and Exchange Commission.
For more information, contact:
Laura E. Owen, President and COO
16801 West 116th Street
Lenexa, KS 66219 USA
Phone: (913) 338-5550
Fax: (913) 312-0264
Lowen@ICOP.com
www.ICOP.com
For Investor Relations:
Elite Financial Communications Group, LLC
Dodi Handy, President and CEO
Phone: (407) 585-1080
ICOP@efcg.net
SOURCE ICOP Digital, Inc.
----------------------------------------------
Laura E. Owen
President and COO of ICOP Digital
Inc.
+1-913-338-5550
Fax
+1-913-312-0264
Lowen@ICOP.com; or Investors
Dodi Handy
President and CEO of Elite Financial Communications Group
LLC
+1-407-585-1080
ICOP@efcg.net
MOVE 3.41 House Hunters Stay Ahead in Real Estate with Industry's Most up-to-the Minute Listing Information
REALTOR.com(R) Leads Industry, Updates 500,000 Listings Every 15 Minutes
Jul 30, 2007 9:03:00 AM
Copyright Business Wire 2007
LOS ANGELES--(BUSINESS WIRE)--
While purchasing a home is an exciting milestone, it's also a major investment requiring relevant, accurate and comprehensive information. REALTOR.com, the nation's most comprehensive real estate network, today announces it has begun updating property listings every 15 minutes, more often than any other real estate search website.
By increasing MLS listing updates from once-a-day to every 15 minutes in participating metro areas, REALTOR.com now offers house hunters up-to-the minute comprehensive data on new listings, price changes and important property details to help them make better decisions on prospective homes.
"Nothing's more frustrating than going online to research properties and finding you're basing a decision on old or out-of-date information," says REALTOR.com President Errol Samuelson. "With 15-minute MLS updates, consumers now have access to comprehensive information on listings in as close to real time as possible. This means a seller's home will be visible to potential buyers faster and buyers will be able to find new homes or price reductions faster."
While many real estate web sites update listings once a day or less frequently, REALTOR.com began updating listings up to four times per hour so consumer searches yield the most accurate results in the industry. This means the 5.3 million monthly consumers on REALTOR.com will have the edge because they will have early access to new listings, price changes, expanded descriptions and new photos.
"We know buying a home is one of the biggest investments most people make," says Samuelson. "By delivering the freshest and most comprehensive data possible, REALTOR.com is providing consumers with the information they need to make better decisions."
REALTOR.com is currently updating listings from nearly half of the 900 MLS systems across the US multiple times per day. The company hopes to increase the number of properties being updated in 15 minute increments from more than 500,000 every 15 minutes today to more than a million later this year.
When searching for a home, most consumers sort by price range and property features. With the freshest data in the industry, REALTOR.com provides consumers with the full range of listed properties falling within their search criteria, including homes with added property details or price changes announced within the last 15 minutes.
"We're very excited and eager to give house hunters the freshest and most accurate data possible," Samuelson says. "We know stale or old information can lead to missed opportunities and poor decisions. In working with our MLS partners to deliver 15 minute updates, the consumer can be confident that REALTOR.com is the industry's most trusted information source."
Some of the major metro areas that REALTOR.com is pulling data from in 15 minute increments include Washington DC and Baltimore, Atlanta, Orange County, Boston, Memphis, Las Vegas, Ft. Myers, Cincinnati, Northern Michigan, North San Francisco Bay area and the Silicon Valley, and San Jose.
ABOUT REALTOR.COM(R)
Realtor.com(R), "Where the world shops for real estate online", is operated by Move, Inc., and is the official Web site of the National Association of REALTORS(R). Ranked as the No. 1 homes-for-sale site, REALTOR.com(R) currently offers potential home buyers access to over four million property listings as well as the most brokers and agents to contact. The site also provides REALTORS(R) and the home sellers they represent with the Internet's largest real estate marketplace, reaching more than 5.3 million consumers in June 2007(1). Agents and companies have the power to customize the resources of the REALTOR.com(R) Web site to maximize their brand and productivity. The REALTOR.com(R) Web site (www.realtor.com) is operated by Move, Inc. (NASDAQ:MOVE).
REALTOR(R) and REALTOR.com(R) are registered trademarks of the NATIONAL ASSOCIATION OF REALTORS(R). REALTOR(R) is a federally registered collective membership mark, which identifies a real estate professional who is a Member of the NATIONAL ASSOCIATION OF REALTORS(R) and subscribes to its strict Code of Ethics.
This press release may contain forward-looking statements, including information about management's view of Move's future expectations, plans and prospects, within the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other factors which may cause the results of Move, its subsidiaries, divisions and concepts to be materially different than those expressed or implied in such statements. These risk factors and others are included from time to time in documents Move files with the Securities and Exchange Commission, including but not limited to, its Form 10-Ks, Form 10-Qs and Form 8-Ks. Other unknown or unpredictable factors also could have material adverse effects on Move's future results. The forward-looking statements included in this press release are made only as of the date hereof. Move cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, Move expressly disclaims any intent or obligation to update any forward-looking statements to reflect subsequent events or circumstances.
(1) comScore Media Metrix, June 2007
Source: REALTOR.com
----------------------------------------------
Move Inc.
Julie Reynolds
805-557-3080
julie.reynolds@move.com
or
The Rogers Group
Jessica Schmidt
310-552-4177
jschmidt@rogerspr.com
F 8.29 Ford Announces Number of Premium Shares to be Paid in Its Conversion Offer
Jul 30, 2007 8:54:00 AM
DEARBORN, Mich., July 30 /PRNewswire-FirstCall/ -- Ford Motor Company (NYSE: F) ("Ford") today announced the number of shares of Ford common stock that will constitute the premium to be paid in connection with its conversion offer related to the outstanding 6.50% Cumulative Convertible Trust Preferred Securities of Ford's wholly owned subsidiary trust, Ford Motor Company Capital Trust II. The premium represents the amount of shares of Ford common stock determined by dividing (i) $14.25 by (ii) $8.1576, the volume-weighted average of the reported sales prices on the New York Stock Exchange of Ford common stock during the three trading-day period of July 25, July 26, and July 27, 2007. Accordingly, each trust preferred security validly tendered and accepted for conversion will be converted into an aggregate of 4.5717 shares of Ford's common stock, which includes the premium of 1.7468 shares and 2.8249 shares of Ford common stock issuable pursuant to the conversion terms of the trust preferred securities.
On July 2, 2007, Ford commenced an offer to pay a premium to holders of any and all trust preferred securities who elect to convert their trust preferred securities to shares of Ford common stock subject to the terms of the offer. The offer is scheduled to expire at 5:00 p.m., New York City time, on Tuesday, July 31, 2007, unless extended or earlier terminated, and is expected to settle on Friday, August 3, 2007. If all trust preferred securities that were outstanding as of the commencement of the offer were validly tendered and accepted for conversion, Ford would issue an aggregate of 457,163,141 shares of Ford common stock, including approximately 282,485,762 shares pursuant to the conversion terms of the trust preferred securities, plus an aggregate premium of 174,677,379 shares of Ford common stock.
The conversion offer is being made pursuant to an offering circular dated July 2, 2007, as amended on July 13, 2007, and related documents. The completion of the offer is subject to conditions described in the conversion offer documents. Subject to applicable law, Ford may waive the conditions applicable to the offer or extend, terminate or otherwise amend the offer.
This press release is not an offer to convert, or a solicitation of an offer to convert, any trust preferred securities. The conversion offer is being made only on the terms and subject to the conditions described in the offering circular and related documents, which have been distributed to holders of trust preferred securities, who are advised to read such documents because they contain important information. Copies of the offering circular and related documents have been filed with the Securities and Exchange Commission as exhibits to a Schedule TO, as amended, and are available for free at the Commission's web site at www.sec.gov.
Holders of trust preferred securities may address questions about the conversion offer or make requests for copies of the offering circular and related documents for free to Georgeson, Inc., the information agent for the conversion offer, by calling toll-free at 888-605-7541.
Ford Motor Company Capital Trust II, a statutory business trust, was formed in 2001 under the laws of the state of Delaware and is a wholly-owned subsidiary of Ford Motor Company. Ford Motor Company, a global automotive industry leader based in Dearborn, Mich., manufactures or distributes automobiles in 200 markets across six continents. With about 260,000 employees and about 100 plants worldwide, the company's core and affiliated automotive brands include Ford, Jaguar, Land Rover, Lincoln, Mercury, Volvo and Mazda. The company provides financial services through Ford Motor Credit Company.
SOURCE Ford Motor Company
----------------------------------------------
Media
Becky Sanch
+1-313-594-4410
bsanch@ford.com
Equity Investment Community
Larry Heck
+1-313-594-0613
fordir@ford.com
Fixed Income Investment Community
Rob Moeller
+1-313-621-0881
fixedinc@ford.com
all of Ford Motor Company; or Investor Inquiries
Georgeson
Inc.
+1-888-605-7541